Immunobridging efficacy of a tetravalent dengue vaccine against dengue and against hospitalized dengue from children/adolescents to adults in highly endemic countries.
Ying HuangZoe MoodieMichal JuraskaYouyi FongLindsay N CarppLaurent ChambonneauDiana L CoronelGustavo H DayanCarlos A DiazGranadosPeter B GilbertPublished in: Transactions of the Royal Society of Tropical Medicine and Hygiene (2021)
VE M0→M25 against DENV-Any and VE against HVCD-DENV-AnyM0→M72 are both expected to be higher in 18-45 and 46-50-y-olds vs CYD14 and CYD15 9-16-y-olds.